247 related articles for article (PubMed ID: 33579221)
1. A 4-gene signature predicts prognosis of uterine serous carcinoma.
Chen H; Li L; Qin P; Xiong H; Chen R; Zhang M; Jiang Q
BMC Cancer; 2021 Feb; 21(1):154. PubMed ID: 33579221
[TBL] [Abstract][Full Text] [Related]
2. A 73-gene proliferative transcriptomic signature predicts uterine serous carcinoma patient survival and response to primary therapy.
Tran LKH; Tran PMH; Mysona DP; Purohit SB; Myers E; Lee WS; Dun B; Xu D; Liu H; Hopkins D; Nechtman J; Scelsi CL; Mittal PK; Kleven D; Wallbillich JJ; Rungruang B; Ghamande S; She JX
Gynecol Oncol; 2020 May; 157(2):340-347. PubMed ID: 32067813
[TBL] [Abstract][Full Text] [Related]
3. Gene expression profiles in stage I uterine serous carcinoma in comparison to grade 3 and grade 1 stage I endometrioid adenocarcinoma.
Mhawech-Fauceglia P; Wang D; Kesterson J; Syriac S; Clark K; Frederick PJ; Lele S; Liu S
PLoS One; 2011 Mar; 6(3):e18066. PubMed ID: 21448288
[TBL] [Abstract][Full Text] [Related]
4. HER2 in uterine serous carcinoma: Current state and clinical perspectives.
Navarro Sanchez JM; Finkelman BS; Turner BM; Katerji H; Wang X; Varghese S; Wang T; Peng Y; Hicks DG; Zhang H
Am J Clin Pathol; 2023 Oct; 160(4):341-351. PubMed ID: 37267036
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer.
Bonazzoli E; Predolini F; Cocco E; Bellone S; Altwerger G; Menderes G; Zammataro L; Bianchi A; Pettinella F; Riccio F; Han C; Yadav G; Lopez S; Manzano A; Manara P; Buza N; Hui P; Wong S; Litkouhi B; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Schlessinger J; Santin AD
Clin Cancer Res; 2018 Oct; 24(19):4845-4853. PubMed ID: 29941483
[No Abstract] [Full Text] [Related]
6. The comparison of pure uterine serous carcinoma and mixed tumor with serous component: a single-institution review of 91 cases.
You X; Dong Y; Wang J; Cheng Y; Jia Y; Zhang X; Wang J
BMC Cancer; 2024 Jan; 24(1):99. PubMed ID: 38233757
[TBL] [Abstract][Full Text] [Related]
7. Microarray analysis reveals distinct gene expression profiles among different tumor histology, stage and disease outcomes in endometrial adenocarcinoma.
Mhawech-Fauceglia P; Wang D; Kesterson J; Clark K; Monhollen L; Odunsi K; Lele S; Liu S
PLoS One; 2010 Nov; 5(11):e15415. PubMed ID: 21079744
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors for patients with early-stage uterine serous carcinoma without adjuvant therapy.
Tate K; Yoshida H; Ishikawa M; Uehara T; Ikeda SI; Hiraoka N; Kato T
J Gynecol Oncol; 2018 May; 29(3):e34. PubMed ID: 29533019
[TBL] [Abstract][Full Text] [Related]
9. Uterine carcinosarcoma and high-risk endometrial carcinomas: a clinicopathological comparison.
Zhang C; Hu W; Jia N; Li Q; Hua K; Tao X; Wang L; Feng W
Int J Gynecol Cancer; 2015 May; 25(4):629-36. PubMed ID: 25633654
[TBL] [Abstract][Full Text] [Related]
10. Monitoring Treatment Response, Early Recurrence, and Survival in Uterine Serous Carcinoma and Carcinosarcoma Patients Using Personalized Circulating Tumor DNA Biomarkers.
Bellone S; McNamara B; Mutlu L; Demirkiran C; Hartwich TMP; Harold J; Yang-Hartwich Y; Siegel ER; Santin AD
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240216
[TBL] [Abstract][Full Text] [Related]
11. Poor prognosis of uterine serous carcinoma compared with grade 3 endometrioid carcinoma in early stage patients.
Park JY; Nam JH; Kim YT; Kim YM; Kim JH; Kim DY; Sohn I; Lee SW; Sung CO; Kim KR
Virchows Arch; 2013 Mar; 462(3):289-96. PubMed ID: 23417747
[TBL] [Abstract][Full Text] [Related]
12. Novel targeted therapies in uterine serous carcinoma, an aggressive variant of endometrial cancer.
Menderes G; Clark M; Santin AD
Discov Med; 2016 Apr; 21(116):293-303. PubMed ID: 27232515
[TBL] [Abstract][Full Text] [Related]
13. Uterine Papillary Serous Carcinoma: A Single-Institution Review of 62 Cases.
Black C; Feng A; Bittinger S; Quinn M; Neesham D; McNally O
Int J Gynecol Cancer; 2016 Jan; 26(1):133-40. PubMed ID: 26588230
[TBL] [Abstract][Full Text] [Related]
14. Cox-LASSO Analysis Reveals a Ten-lncRNA Signature to Predict Outcomes in Patients with High-Grade Serous Ovarian Cancer.
Xu L; Wu Y; Che X; Zhao J; Wang F; Wang P; Qu X; Liu Y; Li Z
DNA Cell Biol; 2019 Dec; 38(12):1519-1528. PubMed ID: 31657627
[TBL] [Abstract][Full Text] [Related]
15. A five-DNA methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinoma.
Guo W; Zhu L; Yu M; Zhu R; Chen Q; Wang Q
Clin Epigenetics; 2018 Nov; 10(1):142. PubMed ID: 30446011
[TBL] [Abstract][Full Text] [Related]
16. Bioinformatic profiling identifies a platinum-resistant-related risk signature for ovarian cancer.
Wu C; He L; Wei Q; Li Q; Jiang L; Zhao L; Wang C; Li J; Wei M
Cancer Med; 2020 Feb; 9(3):1242-1253. PubMed ID: 31856408
[TBL] [Abstract][Full Text] [Related]
17. Correlation of tumor size with other prognostic factors in uterine serous carcinoma: a large multi-institutional study.
Winer I; Mahdi H; Bandyopadhyay S; Semaan A; Van de Vijver KK; Nucci MR; Abdul-Karim F; Hussein Y; Qureshi F; Hayek K; Alosh B; Schulz D; Cote M; Munkarah A; Morris R; Oliva E; Ali-Fehmi R
Gynecol Oncol; 2013 Feb; 128(2):316-21. PubMed ID: 23138135
[TBL] [Abstract][Full Text] [Related]
18. Identification of a RNA-seq-based signature to improve prognostics for uterine sarcoma.
Zhou JG; Zhao HT; Jin SH; Tian X; Ma H
Gynecol Oncol; 2019 Dec; 155(3):499-507. PubMed ID: 31662204
[TBL] [Abstract][Full Text] [Related]
19. [Diagnosis, treatment and prognosis of uterine serous carcinoma].
Zhang F; Deng LS; Li B; Huang MN; Li XG; Zhang R; Wu LY
Zhonghua Fu Chan Ke Za Zhi; 2020 Dec; 55(12):848-856. PubMed ID: 33355760
[No Abstract] [Full Text] [Related]
20. Uterine serous and grade 3 endometrioid carcinomas: is there a survival difference?
Boruta DM; Gehrig PA; Groben PA; Bae-Jump V; Boggess JF; Fowler WC; Van Le L
Cancer; 2004 Nov; 101(10):2214-21. PubMed ID: 15452833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
